Mallory Morales

CIK: 0001941795

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IMRX

Immuneering Corp

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

IMRX
Immuneering Corp
Feb 3, 2026
Award(A)
Stock Option
Direct
140K shares-
IMRX
Immuneering Corp
Oct 1, 2025
Purchase(P)
Direct
300 shares at avg. $6.39$2K
IMRX
Immuneering Corp
Sep 15, 2025
Award(A)
Direct
14.5K shares at avg. $1.43$21K
IMRX
Immuneering Corp
Feb 5, 2025
Award(A)
Stock Option
Direct
110K shares-
IMRX
Immuneering Corp
Sep 15, 2024
Award(A)
Direct
4.5K shares at avg. $1.62$7K

		Type	Shares	Price		Ownership
Feb 3, 2026	IMRX Immuneering Corp	Award(A) Stock Option	140,000	-	-	Direct
Oct 1, 2025	IMRX Immuneering Corp	Purchase(P)	300	$6.39	$1,917	Direct
Sep 15, 2025	IMRX Immuneering Corp	Award(A)	14,497	$1.43	$20,702	Direct
Feb 5, 2025	IMRX Immuneering Corp	Award(A) Stock Option	110,000	-	-	Direct
Sep 15, 2024	IMRX Immuneering Corp	Award(A)	4,458	$1.62	$7,238	Direct

1-5 of 5 transactions

About Morales Mallory

Morales Mallory (SEC CIK 0001941795) files insider reports with the SEC as SVP Finance, CAO of Immuneering Corp (IMRX).

Signal8 holds 5 ownership filings by Morales Mallory, all Form 4s, filed between Sep 17, 2024 and Feb 5, 2026. Those filings report 5 transactions, from Sep 15, 2024 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Morales Mallory's filings is in CAMBRIDGE, MA.

Recent filings by Morales Mallory

Feb 3, 2026: Grant or award of IMRX derivative securities (Form 4, code A).
Oct 1, 2025: Open-market purchase of IMRX shares (Form 4, code P).
Sep 15, 2025: Grant or award of IMRX shares (Form 4, code A).
Feb 5, 2025: Grant or award of IMRX derivative securities (Form 4, code A).
Sep 15, 2024: Grant or award of IMRX shares (Form 4, code A).

Other insiders filing for Immuneering Corp (IMRX)

Gengos Andrew, Chief Financial Officer
Zeskind Benjamin J., PRESIDENT AND CEO
Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER
Schall Thomas J., Director
HAUSMAN DIANA, Director
CARPENTER ROBERT J, Director

How to read Form 4 transaction codes